



**ADULT MEDICATION GUIDELINE**

**Resonium**

**Scope (Staff):** All WNHS Staff

**Scope (Area):** Obstetrics and Gynaecology

**This document should be read in conjunction with the [Disclaimer](#).**

**Quick Links**

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

**Restrictions**

[Formulary: Unrestricted](#)

**Medication Class**

Cation exchange resins

**Presentation**

**Powder:** 454g (1g of resin exchanges about 1mmol of potassium)

**Storage**

Store at room temperature, below 30°C

**Dose**

**Hyperkalaemia**

**Oral:**

15g three to four times a day as a suspension or paste

**Rectal:**

30g as a daily enema

**Administration**

**Oral**

Mix with 3 - 4 mL water per gram of resin (usually 15g in 50 -100mL). Do not mix with fruit juices

(they contain potassium) or sorbitol (risk of colonic necrosis).

Suspensions should be freshly prepared; do not store > 24 hours.

### **Rectal**

Mix with 5 mL water or glucose 10% solution per gram of resin (usually 30g in 100–150 mL for adults). Retention may be more difficult with water. Retain enema for as long as possible (for at least 9 hours) and follow with colonic irrigation to ensure complete removal of the resin.

### **Monitoring**

- Initially, both oral and rectal routes may be used to reduce potassium concentration more rapidly
- Monitor potassium concentration during treatment and adjust dose if necessary. Monitor other electrolytes regularly as the resin does not only exchange calcium.
- Clinical effect takes several hours at least; in an emergency other measures must be used
- Mild laxatives may be used to treat or prevent constipation; do not use sorbitol or magnesium-containing laxatives; stop treatment if significant constipation occurs.

### **Pregnancy**

**1<sup>st</sup> Trimester:** Considered safe to use\*

**2<sup>nd</sup> Trimester:** Considered safe to use\*

**3<sup>rd</sup> Trimester:** Considered safe to use\*

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

### **Breastfeeding**

Considered safe to use\*

### **Comments**

\*As the medicine is not absorbed from the gastrointestinal tract, short term use of polystyrene sulfonate resins is considered safe to use in pregnancy and breastfeeding if it is the medicine of choice. Monitoring of maternal potassium, calcium, sodium and magnesium levels is required during therapy. If the medicine is used near the time of delivery, monitoring of neonatal potassium levels may also be required.

### **References**

Australian Medicines Handbook. Polystyrene sulfonate resins. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited

2021 Jul 8]. Available from: <https://amhonline.amh.net.au/>

The Royal Women's Hospital. Polystyrene sulfonate resins. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2021 Jul 8]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Resonium, resonium A, polystyrene sulfonate resins, sodium polystyrene sulfonate, hyperkalaemia				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	01/2015	Last Reviewed:	08/07/2021	Review Date:	08/07/2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	02/11/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.          Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.